Myovant Bolsters Executive Team with Key Management Appointments
19 Jul 2017 at 12:00 pm ETPDF Version
BASEL, Switzerland, July 19, 2017 /PRNewswire/ — Myovant Sciences (NYSE: MYOV) today announced that it has strengthened its executive team through the appointment of four key management hires. Matthew Lang, JD, has joined the company as General Counsel and Corporate Secretary; Juan Camilo Arjona Ferreira, MD, has joined as Chief Medical Officer; Teresa Perney, PhD, has joined as Senior Vice President of Regulatory Affairs and Quality Assurance; and Andria Langenberg, MD, has joined as Head of Drug Safety and Pharmacovigilance.
“I am very pleased with the caliber of our new corporate leaders and look forward to working closely with them,” said Lynn Seely, MD, President & Chief Executive Officer of Myovant Sciences. “Each is an accomplished leader with decades of highly relevant experience and shares our commitment to delivering innovative therapies for women’s health and endocrine diseases.”
Mr. Lang was previously Vice President, Head of Global Litigation, Investigations, Employment Law and Information Governance at Gilead Sciences, Inc. At Gilead, in addition to leading core functions within the legal department, Mr. Lang was a member of the company’s Corporate Operating Group, Global Legal Leadership Team, and Global Compliance Committee. Prior to Gilead, Mr. Lang was an attorney at Dechert LLP in New York City. Mr. Lang received his BA in Classical Studies from Queen’s University in Canada and his JD from the University of Pennsylvania Law School.
Dr. Arjona Ferreira was previously Senior Vice President, Clinical Development at Shionogi Inc. At Shionogi, Dr. Arjona Ferreira was responsible for leading the company’s US Clinical Development organization and he served on the company’s US Senior Leadership Team and the Global Scientific Committee. Prior to joining Shionogi, Dr. Arjona Ferreira spent over a decade at Merck & Co. where he was Executive Director of Clinical Research in Women’s Health. At Merck, he chaired the product development teams for all programs in contraception and women’s health. Dr. Arjona Ferreira earned his MD and completed his postgraduate specialist training in Obstetrics and Gynecology at Colegio Mayor del Rosario in Bogota, Colombia.
Dr. Perney was previously Medicine Team Leader for XTANDI® and talazoparib at Pfizer, Inc. Prior to Pfizer, Dr. Perney held positions of increasing responsibility within regulatory affairs at several pharmaceutical companies, including Medivation, Inc., Hoffman-La Roche/Genentech, Inc., and Schering-Plough Corporation. She has global regulatory experience in multiple therapeutic areas including oncology, cardiovascular, metabolic diseases, immunology, and respiratory diseases. Dr. Perney received her BA in Biology from Northwestern University and her PhD in Neurobiology from the University of Chicago.
Dr. Langenberg was previously Vice President of Drug Safety and Pharmacovigilance at Medivation, Inc., where she formerly served as Vice President of Clinical Development. Dr. Langenberg has two decades of experience in drug development and has held positions of increasing responsibility within clinical development at Neosil Inc., Corgentech Inc., BioMarin Pharmaceutical Inc., and Chiron Corporation. Dr. Langenberg is board certified in Internal Medicine and Dermatology and completed her internship and residency at the University of California, San Francisco.
About Myovant Sciences
Myovant Sciences is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for women’s health and endocrine diseases. Myovant’s lead product candidate is relugolix, an oral, once-daily, small molecule that acts as a GnRH receptor antagonist. Myovant has initiated three clinical programs for relugolix consisting of five international Phase 3 clinical trials, two in women with heavy menstrual bleeding associated with uterine fibroids, two in women with endometriosis-associated pain, and one in men with advanced prostate cancer. Myovant is simultaneously developing MVT-602, a kisspeptin agonist, for the treatment of female infertility as part of assisted reproduction. Over time, the company intends to expand its development pipeline to include other potential treatments for women’s health and endocrine diseases. For more information, please visit the company’s website at myovant.com.
This press release contains forward-looking statements, including statements regarding Myovant’s ability to advance the clinical development of its lead product candidate, relugolix, into Phase 3 clinical development in multiple indications and expand its development pipeline. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to, risks associated with the success, cost, and timing of the company’s product development activities and clinical trials. For further information regarding risks and uncertainties affecting Myovant, see Myovant’s publicly available filings with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K filed on June 14, 2017. These forward-looking statements are based on information available to Myovant as of the date of this press release and speak only as of the date of this release. Myovant disclaims any obligation to update these forward-looking statements, except as may be required by law.
View original content with multimedia:http://www.prnewswire.com/news-releases/myovant-bolsters-executive-team-with-key-management-appointments-300491015.html
SOURCE Myovant Sciences